Yes, in my opinion adding more and more and more indications and trials is a negative. Better to focus on getting one indication across the goal line. Get one thing done, get bought out at 10X and let the acquiring big pharma company build out the franchise, which is what they do best. If you really worked in pharma, you know there will never be another Amgen. Big pharma/biotech will not allow it to happen. For biotech investors, relentless focus is the name of the game.
News 
Market Data 
Discover 
